ConductScience.org, home
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
API referenceFor AI assistants

Trial · NCT01390818

Participant flow45

How many started, completed or left each group, period by period.

1 to 20 of 45

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDPimasertib (MSC1936369B) 15mg and SAR245409 30mg Once Daily3
Overall StudySTARTEDPimasertib (MSC1936369B) 30mg and SAR245409 30mg Once Daily3
Overall StudySTARTEDPimasertib (MSC1936369B) 15mg and SAR245409 50mg Once Daily3
Overall StudySTARTEDPimasertib (MSC1936369B) 30mg and SAR245409 50mg Once Daily4
Overall StudySTARTEDPimasertib (MSC1936369B) 60mg and SAR245409 50mg Once Daily4
Overall StudySTARTEDPimasertib (MSC1936369B) 30mg and SAR245409 70mg Once Daily3
Overall StudySTARTEDPimasertib (MSC1936369B) 60mg and SAR245409 70mg Once Daily19
Overall StudySTARTEDPimasertib (MSC1936369B) 90mg and SAR245409 70mg Once Daily14
Overall StudySTARTEDPimasertib (MSC1936369B) 60mg and SAR245409 90mg Once Daily3
Overall StudySTARTEDPimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice Daily3
Overall StudySTARTEDPimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice Daily4
Overall StudySTARTEDTNBC: Pimasertib 60mg and SAR245409 70mg Once Daily26
Overall StudySTARTEDNSCLC: Pimasertib 60mg and SAR245409 70mg Once Daily24
Overall StudySTARTEDCRC: Pimasertib 60mg and SAR245409 70mg Once Daily18
Overall StudySTARTEDMEL: Pimasertib 60mg and SAR245409 70mg Once Daily15
Overall StudyCOMPLETEDPimasertib (MSC1936369B) 15mg and SAR245409 30mg Once Daily3
Overall StudyCOMPLETEDPimasertib (MSC1936369B) 30mg and SAR245409 30mg Once Daily3
Overall StudyCOMPLETEDPimasertib (MSC1936369B) 15mg and SAR245409 50mg Once Daily3
Overall StudyCOMPLETEDPimasertib (MSC1936369B) 30mg and SAR245409 50mg Once Daily4
Overall StudyCOMPLETEDPimasertib (MSC1936369B) 60mg and SAR245409 50mg Once Daily4

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01390818/flow

API referenceFor AI assistants